Detection of pancreatic cancer using antibody microarray-based serum protein profiling

Johan Ingvarsson, Christer Wingren, Anders Carlsson, Peter Ellmark, Britta Wahren, Gunilla Engström, Ulrika Harmenberg, Morten Krogh, Carsten Peterson, Carl Borrebaeck

Research output: Contribution to journalArticlepeer-review


The driving force behind oncoproteomics is to identify protein signatures that are associated with a particular malignancy. Here, we have used a recombinant scFv antibody microarray in an attempt to classify sera derived from pancreatic adenocarcinoma patients versus healthy subjects. Based on analysis of nonfractionated, directly labeled, whole human serum proteomes we have identified a protein signature based on 19 nonredundant analytes, that discriminates between cancer patients and healthy subjects. Furthermore, a potential protein signature, consisting of 21 protein analytes, could be defined that was shown to be associated with cancer patients having a life expectancy of <12 months. Taken together, the data suggest that antibody microarray analysis of complex proteomes will be a useful tool to define disease associated protein signatures.
Original languageEnglish
Pages (from-to)2211-2219
Issue number11
Publication statusPublished - 2008

Subject classification (UKÄ)

  • Immunology in the medical area
  • Biophysics


Dive into the research topics of 'Detection of pancreatic cancer using antibody microarray-based serum protein profiling'. Together they form a unique fingerprint.

Cite this